DOCSLIB.ORG

Managing Chronic Pain in Adults with Or in Recovery from Substance Use Disorders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Managing Chronic Pain in Adults with Or in Recovery from Substance Use Disorders A TREATMENT IMPROVEMENT PROTOCOL Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders TIP 54 A TREATMENT IMPROVEMENT PROTOCOL Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders TIP 54 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment 1 Choke Cherry Road Rockville, MD 20857 Acknowledgments This publication was prepared for the Substance Abuse and Mental Health Services Administration (SAMHSA) by the Knowledge Application Program (KAP), a Joint Venture of The CDM Group, Inc., and JBS International, Inc., under contract numbers 270-04-7049 and 270-09-0307, with SAMHSA, U.S. Department of Health and Human Services (HHS). Christina Currier served as the Government Project Officer. Disclaimer The views, opinions, and content of this publication are those of the authors and do not neces­ sarily reflect the views, opinions, or policies of SAMHSA or HHS. Public Domain Notice All materials appearing in this volume except those taken directly from copyrighted sources are in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. However, this publication may not be reproduced or distributed for a fee without the specific, written authorization of the Office of Communications, SAMHSA, HHS. Electronic Access and Copies of Publication This publication may be ordered from SAMHSA’s Publications Ordering Web page at http://www.store.samhsa.gov. Or, please call SAMHSA at 1-877-SAMHSA-7 (1-877-726-4727) (English and Español). The document can be downloaded from the KAP Web site at http://www.kap.samhsa.gov. Recommended Citation Substance Abuse and Mental Health Services Administration. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders. Treatment Improvement Protocol (TIP) Series 54. HHS Publication No. (SMA) 12-4671. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011. Originating Office Quality Improvement and Workforce Development Branch, Division of Services Improvement, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Rockville, MD 20857. HHS Publication No. (SMA) 12-4671 Printed 2012 ii Contents Consensus Panel ............................................................ vii What Is a TIP? ..............................................................ix TIP Format .................................................................ix TIP Development Process . ix Foreword ...................................................................xi 1—Introduction ............................................................. 1 Chronic Pain Impact .......................................................... 1 Audience.................................................................... 2 Purpose..................................................................... 2 Definitions ................................................................. 2 Pain and Addiction Basics ...................................................... 4 Neurobiology of Pain .......................................................... 4 Chronic Pain ................................................................ 6 Pain’s Effect on Health ........................................................ 7 Neurobiology of Addiction ..................................................... 7 Risk Factors for Addiction ..................................................... 8 Cross-Addiction.............................................................. 9 The Cycle of Chronic Pain and Addiction ......................................... 9 Summary of TIP ............................................................ 11 Key Points ................................................................. 11 2—Patient Assessment ....................................................... 13 Elements of Assessment....................................................... 13 Assessment Tools ............................................................ 13 Assessing Pain and Function ................................................... 15 Screening for Substance Use Disorders ........................................... 20 Referring for Further Assessment ............................................... 23 Psychiatric Comorbidities ..................................................... 24 Assessing Ability To Cope With Chronic Pain .................................... 27 Evaluating Risk of Developing Problematic Opioid Use ............................. 28 Ongoing Assessment ......................................................... 30 Treatment Setting ........................................................... 31 Key Points ................................................................. 32 iii 3—Chronic Pain Management ................................................ 33 Overview of Pain Management ................................................ 33 The Treatment Team ......................................................... 33 Treating Patients in Recovery .................................................. 35 Nonpharmacological Treatments ................................................ 37 Treating Psychiatric Comorbidities .............................................. 39 Opioid Therapy ............................................................. 40 Treating Patients in Medication-Assisted Recovery ................................. 43 Tolerance and Hyperalgesia ................................................... 44 Treating Pain in Patients Who Have Active Addiction............................... 45 Acute Pain Episodes.......................................................... 46 Assessing Treatment Outcomes ................................................. 46 Key Points ................................................................. 48 4—Managing Addiction Risk in Patients Treated With Opioids ..................... 49 Promoting Adherence ........................................................ 49 Urine Drug Testing .......................................................... 51 Inclusion of Family, Friends, and Others ......................................... 54 Nonadherence .............................................................. 54 Tools To Assess Aberrant Drug-Related Behaviors.................................. 56 Documenting Care........................................................... 58 Managing Difficult Conversations............................................... 59 Workplace Safety ............................................................ 59 Discontinuation of Opioid Therapy ............................................. 61 Key Points ................................................................. 63 5—Patient Education and Treatment Agreements................................. 65 The Value of Patient Education................................................. 65 Providing Effective Education .................................................. 66 The Internet as a Source of Patient Education ..................................... 68 Education Content........................................................... 69 Opioid Information .......................................................... 69 Methadone Maintenance Therapy Information..................................... 71 Treatment Agreements ....................................................... 71 Key Points ................................................................. 74 iv Contents Appendix A—Bibliography .................................................... 75 Appendix B—Assessment Tools and Resources .................................... 87 Appendix C—CFR Sample Consent Form and List of Personal Identifiers .............. 91 Appendix D—Resources for Finding Complementary and Alternative Therapy Practitioners. 93 Appendix E—Field Reviewers.................................................. 95 Appendix F—Acknowledgments ................................................ 97 Index...................................................................... 99 Exhibits Exhibit 1-1 Statistics on Substance Use and Chronic Pain in the United States ............ 1 Exhibit 1-2 The Pain Pathways .................................................. 5 Exhibit 1-3 Pain Types......................................................... 6 Exhibit 2-1 Elements of a Comprehensive Patient Assessment ........................ 14 Exhibit 2-2 Tools To Assess Pain Level........................................... 17 Exhibit 2-3 Tools To Assess Several Dimensions of Pain ............................. 18 Exhibit 2-4 Tools To Assess Pain Interference With Life Activities and Functional Capacities........................................... 19 Exhibit 2-5 Items To Include in Substance Use Assessment........................... 20 Exhibit 2-6 DSM-IV-TR Criteria for Substance Abuse and Substance Dependence ................................................. 21 Exhibit 2-7 Steps Following Substance Abuse Assessment............................ 22 Exhibit 2-8 Tools To Screen for Substance Use Disorders ............................ 22 Exhibit 2-9 Elements of Screening, Brief Intervention, and Referral to Treatment ......... 23 Exhibit 2-10 Federal Protection of Patient Health Information ........................ 24 Exhibit 2-11 Tools To Assess Emotional Distress, Anxiety, Pain-Related Fear, and Depression............................................ 26 Exhibit
Load more

Recommended publications
  • Addiction Stigma Language- the Words We Use Matter
    naabt.org The National Alliance of Advocates for Buprenorphine Treatment The Words We Use Matter. Reducing Stigma through Language. Why does language matter? Stigma remains the biggest barrier to addiction treatment faced by patients. Changing the stigma will benefit everyone. It will allow patients to The terminology used to describe addiction has contributed to the stigma. more easily regain their self esteem, allow lawmakers to appropriate Many derogatory, stigmatizing terms were championed throughout the “War funding, allow doctors to treat without disapproval of their peers, allow on Drugs” in an effort to dissuade people from misusing substances. Education insurers to cover treatment, and help the public understand this is a took a backseat, mainly because little was known about the science of medical condition as real as any other. addiction. That has changed, and the language of addiction medicine should be changed to reflect today’s greater understanding. By choosing language Choosing the words we use more carefully is one way we can all make that is not stigmatizing, we can begin to dismantle the negative stereotype a difference and help decrease the stigma. associated with addiction. “…In discussing substance use disorders, words can be powerful when used to inform, clarify, encourage, support, enlighten, and unify. On the other hand, stigmatizing words often discourage, isolate, misinform, shame, and embarrass…” Excerpt from “Substance Use Disorders: A Guide to the Use of Language” published by CSAT and SAMHSA Words to avoid and alternatives. Following are stigmatizing words and phrases which could be replaced Habit or Drug Habit with the suggested “preferred terminology” as a start in reducing the Problem with the terms: Calling addictive disorders a habit denies stigma associated with addiction.
    [Show full text]
  • Opioid-Induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations
    SPECIAL TOPIC SERIES Opioid-induced Hyperalgesia in Humans Molecular Mechanisms and Clinical Considerations Larry F. Chu, MD, MS (BCHM), MS (Epidemiology),* Martin S. Angst, MD,* and David Clark, MD, PhD*w treatment of acute and cancer-related pain. However, Abstract: Opioid-induced hyperalgesia (OIH) is most broadly recent evidence suggests that opioid medications may also defined as a state of nociceptive sensitization caused by exposure be useful for the treatment of chronic noncancer pain, at to opioids. The state is characterized by a paradoxical response least in the short term.3–14 whereby a patient receiving opioids for the treatment of pain Perhaps because of this new evidence, opioid may actually become more sensitive to certain painful stimuli. medications have been increasingly prescribed by primary The type of pain experienced may or may not be different from care physicians and other patient care providers for the original underlying painful condition. Although the precise chronic painful conditions.15,16 Indeed, opioids are molecular mechanism is not yet understood, it is generally among the most common medications prescribed by thought to result from neuroplastic changes in the peripheral physicians in the United States17 and accounted for 235 and central nervous systems that lead to sensitization of million prescriptions in the year 2004.18 pronociceptive pathways. OIH seems to be a distinct, definable, One of the principal factors that differentiate the use and characteristic phenomenon that may explain loss of opioid of opioids for the treatment of pain concerns the duration efficacy in some cases. Clinicians should suspect expression of of intended use.
    [Show full text]
  • Assessment of Emotional Functioning in Pain Treatment Outcome Research
    Assessment of emotional functioning in pain treatment outcome research Robert D. Kerns, Ph.D. VA Connecticut Healthcare System Yale University Running head: Emotional functioning Correspondence: Robert D. Kerns, Ph.D., Psychology Service (116B), VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT 06516; Phone: 203-937- 3841; Fax: 203-937-4951; Electronic mail: [email protected] Emotional Functioning 2 Assessment of Emotional Functioning in Pain Treatment Outcome Research The measurement of emotional functioning as an important outcome in empirical examinations of pain treatment efficacy and effectiveness has not yet been generally adopted in the field. This observation is puzzling given the large and ever expanding empirical literature on the relationship between the experience of pain and negative mood, symptoms of affective distress, and frank psychiatric disorder. For example, Turk (1996), despite noting the high prevalence of psychiatric disorder, particularly depression, among patients referred to multidisciplinary pain clinics, failed to list the assessment of mood or symptoms of affective distress as one of the commonly cited criteria for evaluating pain outcomes from these programs. In a more recent review, Turk (2002) also failed to identify emotional distress as a key index of clinical effectiveness of chronic pain treatment. A casual review of the published outcome research in the past several years fails to identify the inclusion of measures of emotional distress in most studies of pain treatment outcome, other than those designed to evaluate the efficacy of psychological interventions. In a recent edited volume, The Handbook of Pain Assessment (Turk & Melzack, 2001), several contributors specifically encouraged inclusion of measures of psychological distress in the assessment of pain treatment effects (Bradley & McKendree-Smith, 2001; Dworkin, Nagasako, Hetzel, & Farrar, 2001; Okifuji & Turk, 2001).
    [Show full text]
  • Polypharmacy and the Senior Citizen: the Influence of Direct-To-Consumer Advertising
    2021;69:19-25 CLINICAL GETRIATRICS - ORIGINAL INVESTIGATION doi: 10.36150/2499-6564-447 Polypharmacy and the senior citizen: the influence of direct-to-consumer advertising Linda Sperling, DHA, MSN, RN1, Martine B. Fairbanks, Ed.D, MA, BS2 1 College of nursing, University of Phoenix, Arizona, USA; 2 College of doctoral studies, University of Phoenix, Arizona, USA Background. Polypharmacy, or taking five or more medications dai- ly, can lead to poor medication compliance and an increased risk for adverse drug-to-drug interactions that may eventually lead to death. The study was designed to explore the questions of how age, the re- lationship between the physician and patient, and television, radio, magazines and modern electronic technology, such as the Internet, affect patients’ understanding of their medical care. Two main areas addressed in this research study included the pharmaceutical indus- try’s influence on consumer decisions to ask a physician for a particular medication, and the prescribing practices of the physician. Methods. This qualitative phenomenological study began with pre- screening volunteer residents in a nursing home to discover poten- tial participants who met the criteria of using five or more medicines daily. We then interviewed 24 participants who met the criteria, using semi-structured interview questions. Results. Four core themes emerged from this study: professional trust, professional knowledge, communication deficit, and direct-to-consum- Received: April 30, 2020 er advertising. Participants reported trusting their doctors and taking Accepted: November 2, 2020 medications without question, but most knew why they were taking the Correspondence medications. Participants also reported seeing ads for medications, but Linda Sperling DHA, MSN, RN only one reported asking a physician to prescribe the medication.
    [Show full text]
  • Pain Management of Inmates
    PAIN MANAGEMENT OF INMATES Federal Bureau of Prisons Clinical Guidance JUNE 2018 Federal Bureau of Prisons (BOP) Clinical Guidance is made available to the public for informational purposes only. The BOP does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient- specific. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Pain Management of Inmates Clinical Guidance June 2018 TABLE OF CONTENTS 1. PURPOSE OF THIS GUIDANCE.................................................................................................................. 1 2. INTRODUCTION TO PAIN MANAGEMENT IN THE BOP .................................................................................. 1 The Prevalence of Chronic Pain ........................................................................................................ 1 General Principles of Pain Management in the BOP .......................................................................... 2 Multiple Dimensions of Pain Management ................................................................................... 2 Interdisciplinary Pain Rehabilitation (IPR) .................................................................................... 2 Roles
    [Show full text]
  • Amphetamine Sensitization Alters Hippocampal Neuronal Morphology and Memory and Learning Behaviors
    Molecular Psychiatry https://doi.org/10.1038/s41380-020-0809-2 ARTICLE Amphetamine sensitization alters hippocampal neuronal morphology and memory and learning behaviors 1,2,5 1,2 1 Luis Enrique Arroyo-García ● Hiram Tendilla-Beltrán ● Rubén Antonio Vázquez-Roque ● 1 3 3 3 1 Erick Ernesto Jurado-Tapia ● Alfonso Díaz ● Patricia Aguilar-Alonso ● Eduardo Brambila ● Eduardo Monjaraz ● 2 4 1 Fidel De La Cruz ● Antonio Rodríguez-Moreno ● Gonzalo Flores Received: 12 November 2019 / Revised: 29 May 2020 / Accepted: 3 June 2020 © The Author(s), under exclusive licence to Springer Nature Limited 2020 Abstract It is known that continuous abuse of amphetamine (AMPH) results in alterations in neuronal structure and cognitive behaviors related to the reward system. However, the impact of AMPH abuse on the hippocampus remains unknown. The aim of this study was to determine the damage caused by AMPH in the hippocampus in an addiction model. We reproduced the AMPH sensitization model proposed by Robinson et al. in 1997 and performed the novel object recognition test (NORt) to evaluate learning and memory behaviors. After the NORt, we performed Golgi–Cox staining, a 1234567890();,: 1234567890();,: stereological cell count, immunohistochemistry to determine the presence of GFAP, CASP3, and MT-III, and evaluated oxidative stress in the hippocampus. We found that AMPH treatment generates impairment in short- and long-term memories and a decrease in neuronal density in the CA1 region of the hippocampus. The morphological test showed an increase in the total dendritic length, but a decrease in the number of mature spines in the CA1 region. GFAP labeling increased in the CA1 region and MT-III increased in the CA1 and CA3 regions.
    [Show full text]
  • Guidline for the Evidence-Informed Primary Care Management of Low Back Pain
    Guideline for the Evidence-Informed Primary Care Management of Low Back Pain 2nd Edition These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. Guideline Disease/Condition(s) Targeted Specifications Acute and sub-acute low back pain Chronic low back pain Acute and sub-acute sciatica/radiculopathy Chronic sciatica/radiculopathy Category Prevention Diagnosis Evaluation Management Treatment Intended Users Primary health care providers, for example: family physicians, osteopathic physicians, chiro- practors, physical therapists, occupational therapists, nurses, pharmacists, psychologists. Purpose To help Alberta clinicians make evidence-informed decisions about care of patients with non- specific low back pain. Objectives • To increase the use of evidence-informed conservative approaches to the prevention, assessment, diagnosis, and treatment in primary care patients with low back pain • To promote appropriate specialist referrals and use of diagnostic tests in patients with low back pain • To encourage patients to engage in appropriate self-care activities Target Population Adult patients 18 years or older in primary care settings. Exclusions: pregnant women; patients under the age of 18 years; diagnosis or treatment of specific causes of low back pain such as: inpatient treatments (surgical treatments); referred pain (from abdomen, kidney, ovary, pelvis,
    [Show full text]
  • Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1
    Opioid Weaning Guidance Document Primary Care GENERAL CONSIDERATIONS: 1. Determine if the goal is a dose reduction or complete discontinuation of agent(s). 2. Weans should occur gradually to minimize the risk of withdrawal symptoms. Weaning opioids may take 6 months or more depending on the total opioid dose and the individual patient’s response to the opioid wean. There is no need to rush this process as this may only cause more distress for the patient. 3. Optimize non-opioid pain management strategies. This link provides options for non-opioid strategies: https://www.cdc.gov/drugoverdose/pdf/alternative_treatments-a.pdf a. Recommend implementing one non-opioid agent at a time b. Evaluate and discontinue any agents that are ineffective c. Do not exceed maximum recommended doses or combine multiple agents from the same medication class d. Avoid use of benzodiazepines or any sedative hypnotic agents 4. Set expectations and functional goals with patient prior to initiation of the opioid wean. 5. Educate patient on the change in opioid tolerance over time during the opioid wean and risk for overdose if they resume their starting dose or a previously stable higher dose. Discuss/prescribe naloxone to minimize the risk of overdose. 6. Screen for and treat any untreated/under-treated depression. Depression may make the weaning process more challenging. MORPHINE EQUIVALENT DOSE CALCULATOR: 1. Link to calculator: http://www.agencymeddirectors.wa.gov/Calculator/DoseCalculator.htm 2. This calculator can be utilized to determine the current morphine equivalent dose your patient is receiving at baseline. If the goal is for opioid dose reduction, this calculator can also be used to determine your goal “ending” dose.
    [Show full text]
  • Addiction and Substance Abuse in Anesthesiology Ethan O
    Ⅵ REVIEW ARTICLES David S. Warner, M.D., and Mark A. Warner, M.D., Editors Anesthesiology 2008; 109:905–17 Copyright © 2008, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Addiction and Substance Abuse in Anesthesiology Ethan O. Bryson, M.D.,* Jeffrey H. Silverstein, M.D.† Despite substantial advances in our understanding of addic- idents, and 19% reported at least one pretreatment tion and the technology and therapeutic approaches used to fatality.2 Substantial advances have occurred in our fight this disease, addiction still remains a major issue in the understanding of addiction as well as both the tech- anesthesia workplace, and outcomes have not appreciably changed. Although alcoholism and other forms of impair- nology and therapeutic approaches used to fight this ment, such as addiction to other substances and mental ill- disease, although outcomes have not appreciably ness, impact anesthesiologists at rates similar to those in changed. Starting with a brief review of the basic other professions, as recently as 2005, the drug of choice for concepts of addiction, this article highlights the cur- anesthesiologists entering treatment was still an opioid. rent thoughts regarding the pathophysiologic basis of There exists a considerable association between chemical dependence and other psychopathology, and successful addiction, as well as clinical manifestations, legal is- treatment for addiction is less likely when comorbid psycho- sues, and treatment strategies. pathology is not treated. Individuals under evaluation or Anesthesiologists (as well as any physician) may suffer treatment for substance abuse should have an evaluation from addiction to any number of substances, though with subsequent management of comorbid psychiatric con- addiction to opioids remains the most common.
    [Show full text]
  • DSM-IV Pain Disorder in the General Population an Exploration of the Structure and Threshold of Medically Unexplained Pain Symptoms
    DSM-IV pain disorder in the general population An exploration of the structure and threshold of medically unexplained pain symptoms Christine Fröhlich,· Frank Jacobi, Hans-Ulrich Wittchen Received: 18 March 2005 / Accepted: 12 September 2005 / Published online: 18 November 2005 Abstract Background Despite an abundance of questionnaire data, the prevalence of clinically significant and medically unexplained pain syndromes in the general population has rarely been examined with a rigid personal-interview methodology. Objective To examine the prevalence of pain syndromes and DSM- IV pain disorder in the general population and the association with other mental disorders, as well as effects on disability and health-care utilization. Methods Analyses were based on a community sample of 4.181 participants 18–65 years old; diagnostic variables were assessed with a standardized diagnostic interview (M-CIDI). Results The 12-month prevalence for DSM-IV pain disorder in the general population was 8.1%; more than 53% showed concurrent anxiety and mood disorders. Subjects with pain disorder revealed significantly poorer quality of life, greater disability, and higher health-care utilization rates compared to cases with pain below the diagnostic threshold. The majority had more than one type of pain, with excessive headache being the most frequent type. Conclusions Even when stringent diagnostic criteria are used, pain disorder ranks among the most prevalent conditions in the community. The joint effects of high prevalence in all age groups, substantial disability, and increased health services utilization result in a substantial total burden, exceeding that of depression and anxiety. Key words: DSM-IV pain disorder, pain syndromes, comorbidity, impairment, Composite International Diagnostic Interview (CIDI) Introduction Chronic pain is well known as a highly prevalent condition in the general population.
    [Show full text]
  • Assessment and Measurement of Pain and Pain Treatment
    2 Assessment and measurement of pain and pain treatment Section Editor: Prof David A Scott 2 2.1 | Assessment Contributors: Prof David A Scott, Dr Andrew Stewart 2.2 | Measurement Contributors: Prof David A Scott, Dr Andrew Stewart 2.3 | Outcome measures in acute pain management Contributors: Prof David A Scott, Dr Andrew Stewart 5th Edition | Acute Pain Management: Scientific Evidence 3 2.0 | Assessment and measurement of pain and pain treatment Reliable and accurate assessment of acute pain is necessary to ensure safe and effective pain management and to provide effective research outcome data. The assessment and measurement of pain is fundamental to the process of assisting in the diagnosis of the cause of a patient’s pain, selecting an appropriate analgesic therapy and evaluating then modifying that therapy according to the individual patient’s response. Pain should be assessed within a sociopsychobiomedical model that recognises that physiological, psychological and environmental factors influence the overall pain experience. Likewise, the decision regarding the appropriate intervention following assessment needs to be made with regard to a number of factors, including recent therapy, potential risks and side effects, any management plan for the particular patient and the patient’s own preferences. A given pain ‘rating’ should not automatically trigger a specific intervention without such considerations being undertaken (van Dijk 2012a Level IV, n=2,674; van Dijk 2012b Level IV, n=10,434). Care must be undertaken with pain assessment to avoid the process of assessment itself acting as a nocebo (see Section 1.3). 2.1 | Assessment The assessment of acute pain should include a thorough general medical history and physical examination, a specific “pain history” (see Table 2.1) and an evaluation of associated functional impairment (see Section 2.3).
    [Show full text]
  • About Pain Pharmacology: What Pain Physicians Should Know Kyung-Hoon Kim1, Hyo-Jung Seo1, Salahadin Abdi2, and Billy Huh2
    Korean J Pain 2020;33(2):108-120 https://doi.org/10.3344/kjp.2020.33.2.108 pISSN 2005-9159 eISSN 2093-0569 Review Article All about pain pharmacology: what pain physicians should know Kyung-Hoon Kim1, Hyo-Jung Seo1, Salahadin Abdi2, and Billy Huh2 1Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Yangsan, Korea 2Department of Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Received February 8, 2020 Revised March 12, 2020 From the perspective of the definition of pain, pain can be divided into emotional Accepted March 13, 2020 and sensory components, which originate from potential and actual tissue dam- age, respectively. The pharmacologic treatment of the emotional pain component Correspondence includes antianxiety drugs, antidepressants, and antipsychotics. The anti-anxiety Kyung-Hoon Kim drugs have anti-anxious, sedative, and somnolent effects. The antipsychotics are Department of Anesthesia and Pain effective in patients with positive symptoms of psychosis. On the other hand, the Medicine, Pusan National University sensory pain component can be divided into nociceptive and neuropathic pain. Yangsan Hospital, 20 Geumo-ro, Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are usually applied for Mulgeum-eup, Yangsan 50612, Korea Tel: +82-55-360-1422 somatic and visceral nociceptive pain, respectively; anticonvulsants and antide- Fax: +82-55-360-2149 pressants are administered for the treatment of neuropathic pain with positive and E-mail: [email protected] negative symptoms, respectively. The NSAIDs, which inhibit the cyclo-oxygenase pathway, exhibit anti-inflammatory, antipyretic, and analgesic effects; however, they have a therapeutic ceiling.
    [Show full text]